Rosamaria Nitti

Dr. Rosamaria Nitti

Università Vita-Salute San Raffaele, Milan, Italy
+1
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2021 in Blood
Verified
Journal Article
Closed access
RGRaffaella Greco
Raffaella Greco
RNRosamaria Nitti
Rosamaria Nitti
NMNicasio Mancini
Nicasio Mancini
RPRenée Pasciuta
Renée Pasciuta
FLFrancesca Lorentino
Francesca Lorentino
FCFabio Ciceri
Fabio Ciceri

19 February 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EXElisabetta Xue
Elisabetta Xue
FLFrancesca Lorentino
Francesca Lorentino
MSMaria Teresa Lupo Stanghellini
Maria Teresa Lupo Stanghellini
FGFabio Giglio
Fabio Giglio
SPSimona Piemontese
Simona Piemontese
RGRaffaella Greco
Raffaella Greco
Correlation between risk of graft-versus-host disease (GvHD) and CD3+ counts within the peripheral blood stem cell graft has recently been reported in the setting of post-transplant cyclophosphamide (PT-Cy). We aimed to investigate the benefit of the addition of a single dose of anti-T lymphocyte globulin (ATLG 5 mg/kg) to PT-Cy in this setting. Starting in 2019, all patients receiving PBSC transplant containing CD3+ counts above 300 × 106/kg (study group) received a post-transplant dose of ATLG in addition to standard PT-Cy. The study was designed as a real-life analysis and included all consecutive Hematopoietic Stem Cell Transplantation (HSCT) recipients according to the above-mentioned inclusion criterion (n = 21), excluding cord blood and bone marrow donors. Using a 1:2 matched-pair analysis, we compared the outcomes with a historical population who received PT-Cy only (control group). We found a delayed platelet engraftment (29% vs. 45% at 30 days, p = 0.03) and a non-significant trend toward higher risk of poor graft function (29% vs. 19%, p = 0.52). The addition of ATLG impacted long-term immune reconstitution on the CD4+ subsets, but this did not translate into higher rate of relapse or viral infection. Acute GvHD was not significantly impacted, but 1-year cumulative incidence of chronic GvHD was significantly lower in the study group (15% vs. 41%, p = 0.04). Survival outcomes were comparable. In conclusion PT-Cy and ATLG was overall safe and translated into a low rate of chronic GvHD incidence.

15 January 2023 in Cancers
Verified
Journal Article
Open access
PDF file
SSSara Steffanoni
Sara Steffanoni
CTCalimeri Teresa
Calimeri Teresa
SMSarah Marktel
Sarah Marktel
RNRosamaria Nitti
Rosamaria Nitti
MFMarco Foppoli
Marco Foppoli
AFAndrés José María Ferreri
Andrés José María Ferreri
Background: Consolidation therapy has improved the outcome of newly diagnosed PCNSL patients. Whole-brain radiotherapy (WBRT) was the first consolidation strategy used and represented the gold standard for many years, but at the expense of a high risk of neurotoxicity. Thus, alternative strategies are being investigated in order to improve disease outcomes and to spare the neurocognitive side effects due to WBRT. Methods: We reviewed published studies on PCNSL patients treated with HDC/ASCT, focusing on the efficacy and safety of the conditioning regimens. Prospective and retrospective studies, published in the English language from 1992 to 2022, in high-quality international journals were identified in PubMed. Results: Consolidation with HDC containing highly CNS-penetrating agents (thiotepa, busulfan or BCNU) followed by ASCT provided long-term disease control and survival in PCNSL patients. Two prospective randomized studies, comparing HDC/ASCT versus WBRT, reported similar progression-free survival (PFS) and similar results on the decline in neurocognitive functions in a substantial proportion of patients after WBRT but not after HDC-ASCT. A recent randomized study comparing HDC/ASCT versus non-myeloablative consolidation reported a longer PFS in transplanted patients. Conclusion: ASCT conditioned with regimens, including highly CNS-penetrating agents, represents, to date, the best choice among the available consolidation strategies for fit newly diagnosed PCNSL patients.

14 August 2024 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
AIAzza Ismail
Azza Ismail
RNRosamaria Nitti
Rosamaria Nitti
BSBasil Sharrack
Basil Sharrack
MBManuela Badoglio
Manuela Badoglio
PAPascale Ambron
Pascale Ambron
RGRaffaella Greco
Raffaella Greco